S. Kahraman Et Al. , "252P Impact of HER2 expression levels on survival in patients with hormone receptor positive and HER2 negative advanced breast cancer and treated with ribociclib and palbociclib in combination with endocrine therapy: A real-life data, Turkish Oncology Group study," ESMO OPEN , vol.8, no.1, pp.1-2, 2023
Kahraman, S. Et Al. 2023. 252P Impact of HER2 expression levels on survival in patients with hormone receptor positive and HER2 negative advanced breast cancer and treated with ribociclib and palbociclib in combination with endocrine therapy: A real-life data, Turkish Oncology Group study. ESMO OPEN , vol.8, no.1 , 1-2.
Kahraman, S., Gümüşay, Ö., Başaran, G., Çabuk, D., Aydıner, A., Paydaş, S., ... Şendur, M. A. N.(2023). 252P Impact of HER2 expression levels on survival in patients with hormone receptor positive and HER2 negative advanced breast cancer and treated with ribociclib and palbociclib in combination with endocrine therapy: A real-life data, Turkish Oncology Group study. ESMO OPEN , vol.8, no.1, 1-2.
Kahraman, Seda Et Al. "252P Impact of HER2 expression levels on survival in patients with hormone receptor positive and HER2 negative advanced breast cancer and treated with ribociclib and palbociclib in combination with endocrine therapy: A real-life data, Turkish Oncology Group study," ESMO OPEN , vol.8, no.1, 1-2, 2023
Kahraman, Seda Et Al. "252P Impact of HER2 expression levels on survival in patients with hormone receptor positive and HER2 negative advanced breast cancer and treated with ribociclib and palbociclib in combination with endocrine therapy: A real-life data, Turkish Oncology Group study." ESMO OPEN , vol.8, no.1, pp.1-2, 2023
Kahraman, S. Et Al. (2023) . "252P Impact of HER2 expression levels on survival in patients with hormone receptor positive and HER2 negative advanced breast cancer and treated with ribociclib and palbociclib in combination with endocrine therapy: A real-life data, Turkish Oncology Group study." ESMO OPEN , vol.8, no.1, pp.1-2.
@article{article, author={Seda Kahraman Et Al. }, title={252P Impact of HER2 expression levels on survival in patients with hormone receptor positive and HER2 negative advanced breast cancer and treated with ribociclib and palbociclib in combination with endocrine therapy: A real-life data, Turkish Oncology Group study}, journal={ESMO OPEN}, year=2023, pages={1-2} }